DOP2016000120A - Nuevos inhibidores de dgat2 - Google Patents

Nuevos inhibidores de dgat2

Info

Publication number
DOP2016000120A
DOP2016000120A DO2016000120A DO2016000120A DOP2016000120A DO P2016000120 A DOP2016000120 A DO P2016000120A DO 2016000120 A DO2016000120 A DO 2016000120A DO 2016000120 A DO2016000120 A DO 2016000120A DO P2016000120 A DOP2016000120 A DO P2016000120A
Authority
DO
Dominican Republic
Prior art keywords
new
dgat2 inhibitors
dgat2
inhibitors
compounds
Prior art date
Application number
DO2016000120A
Other languages
English (en)
Inventor
Nicholas Paul Camp
Manisha Naik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000120(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2016000120A publication Critical patent/DOP2016000120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE LA SIGUIENTE FÓRMULA: DONDE R ES H O -CH3; MÉTODOS DE TRATAMIENTO DE PACIENTES PARA HIPERTRIGLICERIDEMIA Y ENFERMEDADES CARDIOVASCULARES QUE INCLUYEN DISLIPIDEMIA Y ATEROSCLEROSIS, Y PROCESOS PARA PREPARAR LOS COMPUESTOS.
DO2016000120A 2013-11-25 2016-05-24 Nuevos inhibidores de dgat2 DOP2016000120A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361908339P 2013-11-25 2013-11-25

Publications (1)

Publication Number Publication Date
DOP2016000120A true DOP2016000120A (es) 2016-06-15

Family

ID=52016867

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000120A DOP2016000120A (es) 2013-11-25 2016-05-24 Nuevos inhibidores de dgat2

Country Status (24)

Country Link
US (1) US9073901B2 (es)
EP (1) EP3074381B1 (es)
JP (1) JP6155395B2 (es)
KR (1) KR20160072252A (es)
CN (1) CN105764889B (es)
AP (1) AP2016009230A0 (es)
AR (1) AR098394A1 (es)
AU (1) AU2014353109B2 (es)
CA (1) CA2928468A1 (es)
CL (1) CL2016001172A1 (es)
CR (1) CR20160216A (es)
DO (1) DOP2016000120A (es)
EA (1) EA201690847A1 (es)
ES (1) ES2695302T3 (es)
HK (1) HK1223367A1 (es)
IL (1) IL245245A0 (es)
MA (1) MA39048B1 (es)
MX (1) MX2016006665A (es)
NZ (1) NZ719444A (es)
PE (1) PE20161099A1 (es)
PH (1) PH12016500963A1 (es)
TN (1) TN2016000146A1 (es)
TW (1) TW201609668A (es)
WO (1) WO2015077299A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982267C (en) 2015-05-20 2019-11-12 Eli Lilly And Company Novel dgat2 inhibitors
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
GB2606804B (en) 2019-07-17 2023-12-27 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
US20230174521A1 (en) 2020-05-18 2023-06-08 Merck Sharp & Dohme Llc Novel diacylglyceride o-acyltransferase 2 inhibitors
AU2021356589A1 (en) 2020-10-08 2023-05-25 Merck Sharp & Dohme Llc Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
KR102993831B1 (ko) 2020-10-08 2026-07-23 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조
MX2023005971A (es) 2020-11-20 2023-06-07 2692372 Ontario Inc Metodos y composicion para las modificaciones de kras.
AU2021409234A1 (en) 2020-12-22 2023-06-29 Merck Sharp & Dohme Llc Preparation of tetrahydroindazole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
AU2023400409A1 (en) 2022-12-02 2025-06-26 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455815A4 (en) 2001-12-19 2006-11-02 Millennium Pharm Inc MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
AU2003253925A1 (en) 2002-07-18 2004-02-09 Banyu Pharmaceutical Co., Ltd. Combination therapy for the treatment of obesity
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EA011671B1 (ru) * 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
US20080200376A1 (en) 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP2013515085A (ja) 2009-12-22 2013-05-02 ジ・アドミニストレイターズ・オブ・ザ・チユレーン・エデユケーシヨナル・フアンド 肥満症および糖尿病を治療するための組成物および方法
WO2011078102A1 (ja) * 2009-12-22 2011-06-30 第一三共株式会社 新規フェノキシピリミジン誘導体
CA2789200C (en) * 2010-03-22 2020-05-26 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
JP2014515008A (ja) * 2011-03-03 2014-06-26 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法
EP2562265A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
AU2013245353A1 (en) * 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors

Also Published As

Publication number Publication date
TN2016000146A1 (en) 2017-10-06
JP6155395B2 (ja) 2017-06-28
EP3074381A1 (en) 2016-10-05
KR20160072252A (ko) 2016-06-22
MX2016006665A (es) 2016-07-26
US9073901B2 (en) 2015-07-07
IL245245A0 (en) 2016-06-30
CL2016001172A1 (es) 2016-12-09
AU2014353109B2 (en) 2017-02-02
EA201690847A1 (ru) 2016-09-30
CA2928468A1 (en) 2015-05-28
US20150148358A1 (en) 2015-05-28
TW201609668A (zh) 2016-03-16
MA39048B1 (fr) 2018-04-30
PH12016500963A1 (en) 2016-06-20
MA39048A1 (fr) 2017-05-31
PE20161099A1 (es) 2016-10-22
NZ719444A (en) 2017-12-22
AP2016009230A0 (en) 2016-05-31
WO2015077299A1 (en) 2015-05-28
AU2014353109A1 (en) 2016-05-12
JP2016539115A (ja) 2016-12-15
EP3074381B1 (en) 2018-07-04
HK1223367A1 (zh) 2017-07-28
CN105764889B (zh) 2018-01-02
CN105764889A (zh) 2016-07-13
CR20160216A (es) 2016-06-27
ES2695302T3 (es) 2019-01-03
AR098394A1 (es) 2016-05-26

Similar Documents

Publication Publication Date Title
CR20160216A (es) Nuevos inhibidores de dgat2
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201691135A1 (ru) Новые ингибиторы глутаминазы
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MX390277B (es) Inhibidores de procesos metabolicos celulares.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CL2017001046A1 (es) Inhibidoes del bromodominio
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
EA201691582A1 (ru) Новые фармацевтические препараты
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
CO6761389A2 (es) Inhibidores de nampt y rock
MX2015011273A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
EA201690844A1 (ru) Ингибиторы gsk-3
DOP2014000253A (es) Inhibidores del nampt
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
MX2016001446A (es) Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена